Cala Health introduced a prescribed wearable neuromodulation therapy that targets essential tremor and Parkinson’s disease, featuring transcutaneous afferent patterned stimulation (TAPS) that measures tremor patterns and delivers individualized nerve stimulation.
The company received $50 million in growth capital from Trinity Capital to scale commercial distribution and product development. The FDA-cleared Cala kIQ Plus device, most recently cleared in March, provides temporary relief for hand tremors and addresses postural and kinetic hand tremor symptoms in adults with Parkinson’s disease. Cala’s system is intended for at-home use under physician direction and builds on prior 510(k) clearances and earlier funding rounds.
For consumers, the device promises nonpharmacologic, on-demand symptom relief that fits daily life, signaling wider demand for wearable bioelectronic therapies that personalize neurological care.
Image Credit: Shutterstock/PeopleImages
Key Themes Behind This Trend
- Personalized Neuromodulation Wearables
- Wearable devices that customize nerve stimulation profiles to individual tremor signatures enabling tailored, nonpharmacologic symptom management.
- Home-based Bioelectronic Therapies
- At-home neuromodulation systems designed for physician-supervised use that decentralize chronic neurological care from clinics to daily environments.
- Data-driven Symptom Analytics
- Continuous tremor measurement and pattern recognition creating rich datasets for predictive algorithms and adaptive therapy refinement.
Where This Applies
- Prescription Medical Wearables
- Programmable, FDA-cleared wearable hardware and integrated software platforms disrupting traditional device sales models and follow-up care.
- Digital Therapeutics and Clinical Software
- Regulated software for therapy personalization and remote monitoring emerging as primary treatment adjuncts to hardware-based neuromodulation.
- Reimbursement and Value-based Payers
- Payer models focused on outcomes and cost offsets from reduced medication use that could reshape coverage for bioelectronic therapies.
